Skip to content
Menu

Cellectar Biosciences, Inc. CLRB

Full chart Compare
Set alert

Price alert · CLRB

All alert types
0.88 USD 0.00 (-0.26%)

Regular-session close

0.91 +0.03 +3.26%

After hours · Nov 19, 4:00 PM ET

0.864 Day range 0.958
0.864 52-week range 4.70
YTD
-70.07%
1 year
-69.13%

 

No chart data for this range yet.
Market cap
8.86M
EPS (ttm)
-2.34
Shares out
41.27M
Forward P/E
-0.10
YTD return
-70.07%
1-year return
-69.13%
50-day average
1.60
200-day average
2.48
Enterprise value
59.34M
Volume
88.11K
Avg volume
96.26K
Open
0.9034
Previous close
0.8852
Day's range
0.864 – 0.958
52-week range
0.864 – 4.70
Beta
1.01
Analysts
Buy
Price target
5.67 (+541.8%)

Key statistics

Free cash flow
-20.48M
Total cash
25.87M
Total debt
530.86K
Return on equity
-796.67%
Short % of float
5.06%

Fundamental scorecard

5 of 25 checks passed on CLRB’s reported financials

ValueGrowthProfitabilityHealthDividend

5of 25 checks passed

  • Value 1 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
CLRB Revenue — quarterly 0
CLRB Net income — quarterly -7.97M
CLRB EPS — quarterly -0.46

Earnings

CLRB recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 18, 2024Sep 1, 2024-0.35-0.55-0.20-57.14%
May 14, 2024Mar 1, 2024-0.50-0.40+0.10+20.00%
Mar 27, 2024Dec 1, 2023-0.59-0.66-0.07-11.86%
Aug 14, 2023Jun 1, 2023-0.69-0.73-0.04-5.80%
May 4, 2023Mar 1, 2023-0.75-0.76-0.01-1.33%
Mar 9, 2023Dec 1, 2022-0.83-0.55+0.28+33.73%

Upgrades / downgrades

CLRB analyst upgrades and downgrades
DateFirmActionFromTo
Dec 11, 2024OppenheimerdownOutperformPerform
Nov 19, 2024OppenheimermainOutperformOutperform
Mar 28, 2024Roth MKMmainBuyBuy
Mar 28, 2024OppenheimerreitOutperformOutperform
Mar 4, 2024Roth MKMreitBuyBuy
Nov 4, 2022HC Wainwright & Co.main—Buy

About Cellectar Biosciences, Inc.

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on CLRB — it syncs with the Stock Master app.

Insider holders

CLRB insider holders
InsiderRelationLatest transactionDateShares held
CARUSO JAMES VChief Executive OfficerStock Award(Grant)Dec 7, 202349,236
KOLEAN CHAD JChief Financial OfficerStock Award(Grant)Dec 7, 202342,578
LEA DARRELL SHANEOfficerStock Award(Grant)Dec 7, 202339,599
LONGCOR JARRODChief Operating OfficerStock Award(Grant)Dec 7, 202353,141
SHUSTOV ANDREIOfficerStock Award(Grant)Dec 7, 202355,037

Institution ownership

CLRB institution ownership
Holder% heldSharesValueReported
Rosalind Advisors, Inc.8.90%3,671,5501.01MSep 29, 2024
AIGH Capital Management LLC7.75%3,197,394881.52KSep 29, 2024
Nantahala Capital Management, LLC6.57%2,712,443747.82KSep 29, 2024
Vanguard Group Inc4.18%1,726,986476.13KSep 29, 2024
Adar1 Capital Management, LLC 2.48%1,022,161281.81KSep 29, 2024
Geode Capital Management, LLC0.85%352,45297.17KSep 29, 2024

Fund ownership

CLRB fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund2.60%1,072,704295.74KSep 29, 2024
Vanguard Extended Market Index Fund1.38%568,753156.81KSep 29, 2024
Fidelity Extended Market Index Fund0.44%179,87749.59KOct 30, 2024
iShares Micro Cap ETF0.20%81,91022.58KOct 30, 2024
Fidelity Total Market Index Fund0.15%61,93917.08KOct 30, 2024
Fidelity Series Total Market Index Fund0.10%42,42611.70KOct 30, 2024